ArticleMedicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents2026
Discovery of quinazoline-based derivatives as novel autophagy inhibitors in pancreatic cancer.
Article in Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Pancreatic cancer remains a highly lethal malignancy with limited treatment options. Given the versatile bioactivity of quinazoline derivatives, which are regarded as a promising scaffold for anticancer drug discovery, we designed and synthesized a series of novel quinazoline analogues. Their cytotoxicity was evaluated in three pancreatic cancer cell lines (HPAC, AsPC-1, and MIA PaCa-2), leading to the identification of compound 5a, which exhibited potent effects across all tested cell lines. Further investigation of anticancer activity indicated that 5a significantly inhibited DNA synthesis, clonogenesis, and migration in MIA PaCa-2 cells. Mechanism study revealed that 5a disrupted autophagy, as evidenced by downregulation of Beclin-1 expression and accumulation of LC3B-II and p62, through a mechanism independent of the canonical AMPK-mTOR-ULK1 signaling pathway. This study provides a promising active scaffold for the development of anti-pancreatic cancer agents.
Indexed as
Identifiers
42446659What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.